RAMM Pharma Corp. (CSE:RAMM)

Market Cap	1.79M -88.3%
Revenue (ttm)	2.56M -41.7%
Net Income	-8.65M
EPS	-0.07
Shares Out	119.39M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,668
Average Volume	80,440
Open	0.0150
Previous Close	0.0150
Day's Range	0.0150 - 0.0150
52-Week Range	0.0100 - 0.2500
Beta	0.53
RSI	41.38
Earnings Date	Jun 26, 2026

About RAMM Pharma

RAMM Pharma Corp. engages in the research and development, production, and sale of cannabinoid pharmaceutical formulations, pharmaceuticals, cosmetics, nutraceutical products, and resale of medical supplies products in Canada and internationally. It offers Epifractán, a cannabinoid pharmaceutical drug; XALEX 10, a prescription pharmaceutical formulation for the treatment of refractory epilepsy; and NettaLife, a cannabis-based product for pets. The company was formerly known as MTC Growth Fund-I Inc. and changed its name to RAMM Pharma Corp. in ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1987
• Country: Canada
• Stock Exchange: Canadian Securities Exchange
• Ticker Symbol: RAMM

Financial Performance

In fiscal year 2025, RAMM Pharma's revenue was 3.36 million, a decrease of -22.60% compared to the previous year's 4.34 million. Losses were -8.91 million, -46.01% less than in 2024.